Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2014

GlobeNewswire May 9, 2014

Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro

GlobeNewswire May 5, 2014

Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction

GlobeNewswire April 8, 2014

Hemispherx Biopharma, Inc. Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference

GlobeNewswire March 24, 2014

Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference

GlobeNewswire March 19, 2014

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2013

GlobeNewswire March 14, 2014

Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries

GlobeNewswire March 10, 2014

Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees

GlobeNewswire March 10, 2014

Hemispherx Biopharma Publishes Full National Press Club Presentation on Corporate Website

GlobeNewswire February 24, 2014

Hemispherx Biopharma Summarizes Clinical Results Presented in Washington, DC on January 30, 2014 in Conjunction with the American Society for Microbiology (ASM) Biodefense Conference Aimed at Developing a Universal Influenza Vaccine to Prevent Pandemic Influenza Threat

Globe Newswire February 4, 2014

A Clinical Update on the Search for a Universal Flu Vaccine: Presentation in Washington, DC on January 30, 2014 in Conjunction With the American Society for Microbiology (ASM) Biodefense Conference

Globe Newswire January 28, 2014

RDInvesting Provides Investors with Free In-Depth Equity Reports on AMBA, HEB, TIBX and VEM

Accesswire January 23, 2014

Hemispherx Analysis of New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus

Globe Newswire January 22, 2014

Hemispherx Presents New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus

Globe Newswire January 21, 2014

Hemispherx Biopharma to Present on January 15 at the Biotech Showcase Held in Conjunction With the 32nd JP Morgan Healthcare Conference in San Francisco

Globe Newswire January 13, 2014

Hemispherx Biopharma Reports Evidence Based Clinical Potential of a Natural Interferon (IFN) -- Alpha for Infection Control and Treatment of Drug Resistant H7N9 Influenza Virus

Globe Newswire January 7, 2014

Centers for Disease Control Urges Preparation for an Active Seasonal Flu Season

Globe Newswire December 16, 2013

FDA Authorizes Expansion of Ampligen/FluMist Intranasal Clinical Trial Designed to Elicit Potential Protection Against Many Pre-Pandemic Influenza Viruses

Globe Newswire December 9, 2013

Hemispherx Biopharma Appoints New Chief Financial and Chief Accounting Officers

Globe Newswire December 4, 2013

Hemispherx Biopharma and the University of Pittsburgh Collaborate on a Novel Chemokine-Modulatory Program for Cancer Immunotherapies With Ampligen(R) as a Key Component

Globe Newswire December 2, 2013